Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer

Oncology

Volumn 65, Issue 3, 2003, Pages 224-228

  Yasuda, Kazuhito ^a,b   Igishi, Tadashi ^a,b   Kawasaki, Yuji ^b   Yamamoto, Mitsunobu ^b   Kato, Kazuhiro ^b   Matsumoto, Shingo ^a,b   Kotani, Masahiro ^a,b   Sako, Takanori ^a,b   Shigeoka, Yasushi ^a,b   Sugitani, Akinori ^b   Histuda, Yutaka ^a,b   Shimizu, Eiji ^a,b  

^a TOTTORI UNIVERSITY   (Japan)

^b San in Lung Cancer Study Group   (Japan)

Author keywords

Non small cell lung cancer; Paclitaxel, weekly; Phase II trial

Indexed keywords

PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0344737855     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074475     Document Type: Article

References (20)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients form 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
2. Lilenbaum RC, Green MR: Novel chemothera-peutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 1993;11:1391-1402.
3. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lunger cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993;85:388-394.
4. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85:384-388.
5. Rosell R, Gonzalez-Larriba JL, Alberola V, et al: Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: Links between p53 and K-ras gene status and chemosensitivity. Semin Oncol 1995;22:12-18.
6. Schiff PB, Horwitz SB: Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 1981;20:3247-3252.
7. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW: Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988;48:4093-4100.
8. Georgiadis MS, Russell EK, Gazdar AF, Johnson BE: Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin Cancer Res 1997;3:449-454.
9. Fidias P, Supko JG, Martins R, et al: A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001;7:3942-3949.
10. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19:4216-4223.
11. Akerley W, Glantz M, Choy H, et al: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998;16:153-158.
12. Strumberg D, Erhard J, Harstrick A, et al: Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma. Eur J Cancer 1998;34:1290-1292.
13. Fennelly D, Aghajanian C, Shapiro F, et al: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-192.
14. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB: Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20:937-940.
15. Chang AY, Rubins J, Asbury R, Boros L, Hui LF: Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol 2001;28:10-13.
16. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Cancer Res Clin Oncol 1958;53:457-481.
18. Loffler TM, Freund W, Lipke J, Hausamen TU: Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: Results of a phase I/II trial. Semin Oncol 1996;23:32-34.
19. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-86.
20. Chang YF, Li LL, Wu CW, et al: Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 1996;77:14-18.